(MTD) Mettler-Toledo International - Overview
Stock: Balances, Pipettes, Titrators, Weighing, Inspection
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 28.8% |
| Relative Tail Risk | -4.72% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.08 |
| Alpha | -16.33 |
| Character TTM | |
|---|---|
| Beta | 1.123 |
| Beta Downside | 1.110 |
| Drawdowns 3y | |
|---|---|
| Max DD | 39.81% |
| CAGR/Max DD | -0.08 |
Description: MTD Mettler-Toledo International December 17, 2025
Mettler-Toledo International Inc. (NYSE:MTD) designs, manufactures, and services precision weighing and analytical instruments across four geographic clusters (U.S., Swiss, Western Europe, China) plus a catch-all “Other” segment. Its product portfolio spans laboratory balances, pipetting and titration systems, real-time analytics, industrial scales, dimensional measurement tools, and AI-driven retail weighing solutions, all supported by software platforms such as LabX for data management.
Key recent metrics: FY 2023 revenue reached roughly $3.4 billion, with an operating margin of about 13 percent, and the laboratory-automation segment grew ~8 % YoY, outpacing the broader life-sciences tools sector. Primary economic drivers include sustained demand for clinical-diagnostics and biopharma R&D equipment (a post-COVID tailwind) and ongoing supply-chain pressure on semiconductor components that affect the company’s industrial-scale hardware. A sector-wide catalyst is the accelerating adoption of AI-enabled weighing and traceability solutions in food safety and logistics, which aligns with MTD’s retail-weighing product line.
If you want a concise, data-rich snapshot of MTD’s valuation and risk profile, the ValueRay platform provides a quick-look dashboard that can complement your analysis.
Piotroski VR‑10 (Strict, 0-10) 6.5
| Net Income: 835.7m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.25 > 0.02 and ΔFCF/TA -1.51 > 1.0 |
| NWC/Revenue: 2.26% < 20% (prev 0.35%; Δ 1.91% < -1%) |
| CFO/TA 0.28 > 3% & CFO 996.4m > Net Income 835.7m |
| Net Debt (2.14b) to EBITDA (1.23b): 1.74 < 3 |
| Current Ratio: 1.07 > 1.5 & < 3 |
| Outstanding Shares: last quarter (20.6m) vs 12m ago -3.37% < -2% |
| Gross Margin: 58.39% > 18% (prev 0.58%; Δ 5781 % > 0.5%) |
| Asset Turnover: 115.2% > 50% (prev 113.3%; Δ 1.91% > 0%) |
| Interest Coverage Ratio: 16.00 > 6 (EBITDA TTM 1.23b / Interest Expense TTM 69.0m) |
Altman Z'' 10.00
| A: 0.03 (Total Current Assets 1.28b - Total Current Liabilities 1.19b) / Total Assets 3.52b |
| B: 2.54 (Retained Earnings 8.95b / Total Assets 3.52b) |
| C: 0.32 (EBIT TTM 1.10b / Avg Total Assets 3.42b) |
| D: 2.26 (Book Value of Equity 8.54b / Total Liabilities 3.77b) |
| Altman-Z'' Score: 13.00 = AAA |
Beneish M -3.02
| DSRI: 1.03 (Receivables 687.3m/637.2m, Revenue 3.94b/3.76b) |
| GMI: 0.99 (GM 58.39% / 57.55%) |
| AQI: 1.01 (AQ_t 0.40 / AQ_t-1 0.40) |
| SGI: 1.05 (Revenue 3.94b / 3.76b) |
| TATA: -0.05 (NI 835.7m - CFO 996.4m) / TA 3.52b) |
| Beneish M-Score: -3.02 (Cap -4..+1) = AA |
What is the price of MTD shares?
Over the past week, the price has changed by +0.02%, over one month by -7.51%, over three months by -4.59% and over the past year by +1.20%.
Is MTD a buy, sell or hold?
- StrongBuy: 4
- Buy: 0
- Hold: 9
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the MTD price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 1504.2 | 9.5% |
| Analysts Target Price | 1504.2 | 9.5% |
| ValueRay Target Price | 1369.8 | -0.3% |
MTD Fundamental Data Overview February 03, 2026
P/E Forward = 30.3951
P/S = 7.1763
P/B = 3980.9922
P/EG = 5.7584
Revenue TTM = 3.94b USD
EBIT TTM = 1.10b USD
EBITDA TTM = 1.23b USD
Long Term Debt = 2.15b USD (from longTermDebt, last quarter)
Short Term Debt = 63.6m USD (from shortTermDebt, last quarter)
Debt = 2.21b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 2.14b USD (from netDebt column, last quarter)
Enterprise Value = 30.43b USD (28.29b + Debt 2.21b - CCE 69.1m)
Interest Coverage Ratio = 16.00 (Ebit TTM 1.10b / Interest Expense TTM 69.0m)
EV/FCF = 34.21x (Enterprise Value 30.43b / FCF TTM 889.5m)
FCF Yield = 2.92% (FCF TTM 889.5m / Enterprise Value 30.43b)
FCF Margin = 22.57% (FCF TTM 889.5m / Revenue TTM 3.94b)
Net Margin = 21.20% (Net Income TTM 835.7m / Revenue TTM 3.94b)
Gross Margin = 58.39% ((Revenue TTM 3.94b - Cost of Revenue TTM 1.64b) / Revenue TTM)
Gross Margin QoQ = 59.19% (prev 57.19%)
Tobins Q-Ratio = 8.64 (Enterprise Value 30.43b / Total Assets 3.52b)
Interest Expense / Debt = 0.80% (Interest Expense 17.7m / Debt 2.21b)
Taxrate = 19.22% (51.7m / 269.2m)
NOPAT = 891.3m (EBIT 1.10b * (1 - 19.22%))
Current Ratio = 1.07 (Total Current Assets 1.28b / Total Current Liabilities 1.19b)
Debt / Equity = -8.87 (negative equity) (Debt 2.21b / totalStockholderEquity, last quarter -249.2m)
Debt / EBITDA = 1.74 (Net Debt 2.14b / EBITDA 1.23b)
Debt / FCF = 2.41 (Net Debt 2.14b / FCF TTM 889.5m)
Total Stockholder Equity = -204.2m (last 4 quarters mean from totalStockholderEquity)
RoA = 24.43% (Net Income 835.7m / Total Assets 3.52b)
RoE = -409.2% (negative equity) (Net Income TTM 835.7m / Total Stockholder Equity -204.2m)
RoCE = 56.81% (EBIT 1.10b / Capital Employed (Equity -204.2m + L.T.Debt 2.15b))
RoIC = 46.51% (NOPAT 891.3m / Invested Capital 1.92b)
WACC = 9.37% (E(28.29b)/V(30.50b) * Re(10.05%) + D(2.21b)/V(30.50b) * Rd(0.80%) * (1-Tc(0.19)))
Discount Rate = 10.05% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -2.61%
[DCF Debug] Terminal Value 73.69% ; FCFF base≈889.1m ; Y1≈913.2m ; Y5≈1.02b
Fair Price DCF = 583.9 (EV 14.07b - Net Debt 2.14b = Equity 11.93b / Shares 20.4m; r=9.37% [WACC]; 5y FCF grow 2.67% → 2.90% )
EPS Correlation: -37.46 | EPS CAGR: -44.49% | SUE: -4.0 | # QB: 0
Revenue Correlation: -4.27 | Revenue CAGR: -0.19% | SUE: 1.45 | # QB: 2
EPS next Quarter (2026-03-31): EPS=8.95 | Chg30d=+0.030 | Revisions Net=+2 | Analysts=10
EPS next Year (2026-12-31): EPS=45.77 | Chg30d=+0.033 | Revisions Net=+1 | Growth EPS=+8.5% | Growth Revenue=+4.8%